» Articles » PMID: 24857148

The Rising Incidence of Second Cancers: Patterns of Occurrence and Identification of Risk Factors for Children and Adults

Overview
Specialty Oncology
Date 2014 May 27
PMID 24857148
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

As the population of cancer survivors has increased and continues to age, the occurrence of second cancers has risen dramatically-from 9% of all cancer diagnoses in 1975-1979 to 19% in 2005-2009. The Childhood Cancer Survivor Study, a cohort of more than 14,000 childhood cancer survivors with detailed exposure data and long-term follow-up, has substantially contributed to our understanding of the roles of radiotherapy and chemotherapy in second cancer occurrence. In particular, dose-related risks have been demonstrated for second cancers of the breast, thyroid, central nervous system, gastrointestinal tract, and sarcomas following radiation. Cytotoxic chemotherapy-which has long been known to be leukemogenic-also appears to contribute to risk for a range of other second cancer types. Individuals who develop a second cancer are at particularly high risk for developing additional second cancers. A genome-wide association study of survivors of Hodgkin lymphoma who received radiotherapy identified a locus on chromosome 6q21 as being associated with second cancer risk, demonstrating that recent advances in genomics are likely to prove invaluable for elucidating the contribution of genetic susceptibility to second cancer etiology. Among adults, risk of second cancers varies substantially by type of first and second cancer, patient age, and prevalence of second cancer risk factors, including primary cancer treatments, environmental and lifestyle exposures, and genetic susceptibility. Further research is needed to quantify second cancer risks associated with specific etiologic factors and to identify the patients at highest risk of developing a second cancer to target prevention and screening efforts.

Citing Articles

Thyroid Cancer in Childhood Cancer Survivors: Demographic, Clinical, Germline Genetic Characteristics, Treatment, and Outcome.

Yildirim U, Kebudi R, Iribas Celik A, Zulfikar B, Kebudi A J Clin Med. 2025; 14(2).

PMID: 39860595 PMC: 11766211. DOI: 10.3390/jcm14020589.


Second primary non-myeloid malignancies following intensive treatment for adult acute myeloid leukaemia: a Danish population-based cohort study.

Nielsen N, Jensen J, Baech J, Trab T, El-Galaly T, Schollkopf C Lancet Reg Health Eur. 2025; 50():101204.

PMID: 39844882 PMC: 11750488. DOI: 10.1016/j.lanepe.2024.101204.


Socioeconomic determinants of cancer screening adherence among cancer survivors: analysis from the 2020 Behavioral Risk Factor Surveillance System.

Beatrici E, Qian Z, Filipas D, Stone B, Dagnino F, Labban M JNCI Cancer Spectr. 2024; 9(1).

PMID: 39700416 PMC: 11751581. DOI: 10.1093/jncics/pkae127.


Identifying Subsets of Cancer Patients with an Increased Risk of Developing Cutaneous Melanoma: A Surveillance, Epidemiology, and End Results-Based Analysis.

Rohan T, Mandel J, Yang H, Banner L, Joffe D, Zachian R JID Innov. 2024; 5(1):100323.

PMID: 39697982 PMC: 11652854. DOI: 10.1016/j.xjidi.2024.100323.


Risk of second primary cancers in nodal non-Hodgkin lymphoma patients by primary lymph node location: a retrospective cohort population-based study.

Hemade A, Hallit S Ann Med Surg (Lond). 2024; 86(11):6455-6464.

PMID: 39525716 PMC: 11543202. DOI: 10.1097/MS9.0000000000002644.